Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.
Location: Canada
Total raised: $150.5M
Investors 6
| Date | Name | Website |
| - | Logos Capi... | logoscapit... |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | BioImpact ... | bioimpactc... |
| - | OrbiMed | orbimed.co... |
| - | Teralys Ca... | teralyscap... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.09.2019 | Series B | $82.5M | - |
| 22.06.2017 | Series A | $68M | - |
Mentions in press and media 15
| Date | Title | Description |
| 23.03.2021 | Top 10 Medical Technology (MedTech) startups in Canada | Medical technology (MedTech), an industry that combines the power of technology with the capabilities of modern medical practices, is a sector that can by no means be overlooked in the world today. From the simple stethoscope to highly adva... |
| 01.07.2020 | June VC Funding: 65 startups raise over $2.2B with agtech, biotech leading | It is summer for Boston startups indeed. More than 60 startups raised over $2 billion in venture funding in June. Chief among those were Duck Creek Technologies' $230 million round and Indigo Ag's $300 million Series F round. Venture capita... |
| 06.11.2019 | BDC spinout Amplitude Ventures closes half of newly-launched $200 million health fund | Amplitude Ventures, a Montréal-headquartered investment firm focused on health and the life sciences sectors has announced the launch of a targeted $200 million CAD venture fund. The firm is a spin-out of the Business Development Bank of Ca... |
| 06.09.2019 | Repare Therapeutics Raises US$82.5M in Series B Financing | Repare Therapeutics, a St-Laurent, Quebec, Canada and Cambridge, MA-based precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, completed a US$82.5m Series B financing. The round... |
| 05.09.2019 | Repare Therapeutics Lands $82.5M Series B | CAMBRIDGE, MA, Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced today the completion of a $82.5 million Series B financing. >> Clic... |
| 04.09.2019 | Repare Therapeutics Announces US$82.5 Million Series B Financing | - |
| 04.09.2019 | Repare Therapeutics Raises $82.5M Series B Financing | CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced today the completion of a US$82.5 million... |
| 04.09.2019 | Versant's Repare raises $82M to trial synthetic lethality drugs | Repare Therapeutics has raised an $82.5 million series B round to take synthetic lethality drugs into humans. The Versant Ventures-founded biotech plans to start testing ATR inhibitor RP-3500 in the clinic next year while putting a second a... |
| 23.06.2017 | Term Sheet — Friday, June 23 | OPEN MIC, UBER EDITION After Uber CEO Travis Kalanick was fired, one of the (many, many) takes on the news was that Uber’s business model is a bigger problem than its toxic culture. Here’s one example of this take from the Wall Street Journ... |
| 23.06.2017 | Morning Report: Secondary Transactions Said To Weigh On Uber, Bolster Lyft | 0 Shares Email Facebook Twitter LinkedIn Morning Report: Following Uber’s recent struggles and Lyft’s recent fundraising, the market is dinging one and rewarding the other. Can you guess which is which? You could argue that Uber should be w... |
Show more